Close mobile menu×
Close mobile menu

Anne A. Gershon, MD

Board Certifications: 
Pediatric Infectious Diseases, Pediatrics
Not Accepting New Patients
Treats Children
Profile Headshot

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Pediatric Infectious Diseases
  • Pediatrics

Clinical Expertise

  • Hepatitis
  • Herpes
  • Lyme Disease
  • Rheumatic Fever
  • Epstein-Barr Virus Infection

Education & Training

  • Weill Cornell Medical College
  • Internship: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  • Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center

Honors & Awards

Distinguished Women of Smith College, Scientific Achievement Award of the Varicella-Zoster Research Foundation, Distinguished Physician Award of the Pediatric Infectious Disease Society, Distinguished Alumnus of Weill Cornell Medical School, Plotkin Vaccinology Award, the Gold medal of the Sabin Vaccine Institute, the Fleming Award for Lifetime Achievement of the IDSA, and the Lifetime Achievement in Infectious Disease Teaching from the American Academy of Pediatrics. She was awarded an honorary DSc from Smith College in 1993. 

About Anne Gershon

Anne Gershon, MD, was educated at Smith College and Cornell Medical School. She became Professor of Pediatrics at Columbia University College of Physicians and Surgeons, in 1986. Her research has included epidemiology, diagnosis, immunology, latency, prevention, and treatment of varicella and zoster.  Her studies with varicella vaccine of the safety and efficacy of the vaccine in leukemic children and adults were critical to its licensure in the US. She has received research funding from NIH to study the growth and pathogenesis of VZV in cell culture, and latency and reactivation of VZV in humans and animal models almost continuously for over 40 years. Dr. Gershon served on the Committee on Infectious Diseases of the American Academy of Pediatrics ("Red Book" Committee) and the Committee on Immunization Practices (ACIP) of the CDC. She was a member of the Councils of the Infectious Diseases Society of America (IDSA) and the Pediatric Infectious Disease Society (PIDS). She was president of IDSA in 2008-9. She is the author of over 350 publications and has edited 14 books. She has received many professional awards including Distinguished Women of Smith College, Scientific Achievement Award of the Varicella-Zoster Research Foundation, Distinguished Physician Award of the Pediatric Infectious Disease Society, Distinguished Alumnus of Weill Cornell Medical School, Plotkin Vaccinology Award, the Gold medal of the Sabin Vaccine Institute, the Fleming Award for Lifetime Achievement of the IDSA, and the Lifetime Achievement in Infectious Disease Teaching from the American Academy of Pediatrics. She was awarded an honorary DSc from Smith College in 1993.

Academic Titles

  • Professor of Pediatrics at CUMC

Committee/Societies/Council Memberships

Committee on Infectious Diseases of the American Academy of Pediatrics ("Red Book" Committee) and the Committee on Immunization Practices (ACIP) of the CDC.  Member of the CDC’s Working Group for varicella vaccine and played a major role in recommending a second routine dose of the vaccine for all children in 2006.  Member of the Councils of the Infectious Diseases Society of America (IDSA) and the Pediatric Infectious Disease Society.  She was President of IDSA in 2008-9. 

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Morgan Stanley Children's Hospital

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
3959 Broadway
BHN 106
New York, New York 10032
Phone:
(212) 305-9445
Fax:
(212) 342-5218
Primary

Research

Dr. Gerson's research has included epidemiology, diagnosis, immunology, latency, prevention, and treatment of varicella and zoster.   Her studies with varicella vaccine which examined the safety and efficacy of the vaccine in leukemic children and adults were critical to its licensure; the vaccine is now recommended for all healthy varicella susceptible individuals in the United States.  She is continuing to study the safety and efficacy of varicella vaccine in the “vaccine era”.  She has also focused on HIV infection in children, particularly with regard to opportunistic infections.  She has received research funding from NIH to study the growth  and pathogenesis of VZV in cell culture,  and latency and reactivation of VZV in humans and animal models almost continuously for over 40  years.

Basic studies on VZV, in conjunction with Dr. Michael Gershon in Cell Biology (at Columbia) included identification of the mannose-6-phosphate (MPR), a major receptor for VZV, the mechanism of assembly of VZV in cells, and identification of two different types of spread of VZV, from one cell to another and the other by release of cell free VZV in cells of the superficial epidermis, one of the few cells in the body where MPRs are not present. The release of cell free VZV in the superficial epidermis accounts for spread of virus from one individual to another. It also accounts for development of latent infection in patients with varicella. More recently, she and her co-workers have investigated latent infection with VZV in humans (autopsy and surgical specimens) and in an in vitro model of latency and reactivation of VZV utilizing enteric neurons of the guinea pig. Enteric ganglia can be dissected from guinea pigs, cultivated in vitro, and infected with cell free VZV with survival for weeks. The neurons in these cultures manifest VZV infection, which have the latency signature of the virus: expression of genes 4, 21, 29, 62, 63, and 66; transcripts and proteins of these regulatory genes are found only in the cell cytoplasm. This signature matches the one also demonstrated in surgical specimens from human gut that contained enteric neurons in which VZV was found to be latent. In vitro upon introduction of VZV gene 61 to a latently infected guinea pig enteric neuron, the virus reactivates to express all 70 of its genes, and the neuron dies. This unique experimental demonstration of latent infection in intestinal ganglia of guinea pigs was what led to the exploration of whether VZV could be latent in the human gut, leading to conditions such as gastric and intestinal ulcers and pseudoobstruction if reactivation of virus occurs in the enteric nervous system.

Research Interests

  • Latency and reactivation of varicella zoster virus (VZV) in vivo and in vitro
  • Vaccine safety of varicella and zoster vaccines, including molecular identification
  • Gastrointestinal diseases caused by VZV in patients and in guinea pig model

Grants

ANTI-VIRAL THERAPY IN ALZHEIMER S DISEASE (Federal Gov)

Sep 15 2017 - May 31 2022

VZV IN THE ENS: PATHOGENESIS AND CONSEQUENCES (Federal Gov)

Mar 1 2017 - Feb 28 2021

COLUMBIA UNIVERSITY CISA CENTER (Federal Gov)

Sep 27 2012 - Sep 26 2017

V212 PN00 1, A PHASE 111, RANDOMIZED, PLACEBO-CONTROLLED, CL INICAL TRIAL TO STUDY THE SAFETY, AND EFFICACY, OF V212 IN A (Private)

Jul 1 2011 - Dec 31 2016

VARICELLA ZOSTER VIRUS IDENTIFICATION PROGRAM (VZVIP) SUPPORT (Private)

Mar 1 2012 - Dec 31 2013

COLUMBIA COLLABORATIVE HIV/AIDS CLINICAL TRIALS UNIT (Federal Gov)

Feb 1 2007 - Nov 30 2013

VACCINE SAFETY SURVEILLANCE AND ASSESSMENT (Federal Gov)

Sep 20 2002 - Sep 19 2012

RELATIONSHIP OF IL-10 PRODUCTION AND IMMUNE RESPONSES TO VARICELLA-ZOSTER VIRUS (VZV) IN ELDERLY RECIPIENTS OF ZOSTAVAX (Private)

Feb 15 2011 - Feb 14 2012

TRAINING IN PEDIATRIC INFECTIOUS DISEASE (Federal Gov)

Sep 30 1998 - Aug 31 2009

VARICELLA-ZOSTER VIRUS--RECEPTORS AND INFECTIVE MECHANISMS (Federal Gov)

Dec 1 1989 - Mar 31 2009